The online version of this article (doi:10.1186/1475-2875-11-143) contains supplementary material, which is available to authorized users.
The authors declare that they have no competing interests.
JAS and KMJ conceived the project. KMJ, JAS and SBD implemented the designs in POPT. KMJ wrote the first draft of the manuscript. JAS, SBD, JT, NL, and NJW revised the manuscript critically for important intellectual content. All authors read and approved the final manuscript.
Artemisinin-based combination therapy (ACT) is currently recommended as first-line treatment for uncomplicated malaria, but of concern, it has been observed that the effectiveness of the main artemisinin derivative, artesunate, has been diminished due to parasite resistance. This reduction in effect highlights the importance of the partner drugs in ACT and provides motivation to gain more knowledge of their pharmacokinetic (PK) properties via population PK studies. Optimal design methodology has been developed for population PK studies, which analytically determines a sampling schedule that is clinically feasible and yields precise estimation of model parameters. In this work, optimal design methodology was used to determine sampling designs for typical future population PK studies of the partner drugs (mefloquine, lumefantrine, piperaquine and amodiaquine) co-administered with artemisinin derivatives.
The optimal designs were determined using freely available software and were based on structural PK models from the literature and the key specifications of 100 patients with five samples per patient, with one sample taken on the seventh day of treatment. The derived optimal designs were then evaluated via a simulation-estimation procedure.
For all partner drugs, designs consisting of two sampling schedules (50 patients per schedule) with five samples per patient resulted in acceptable precision of the model parameter estimates.
The sampling schedules proposed in this paper should be considered in future population pharmacokinetic studies where intensive sampling over many days or weeks of follow-up is not possible due to either ethical, logistic or economical reasons.
Additional file 1: Displays the unpublished two-compartment model for desethylamodiaquine and the results from the evaluation of the designs [ 29]. (PDF 67 KB)
Authors’ original file for figure 112936_2011_2109_MOESM2_ESM.gif
Authors’ original file for figure 212936_2011_2109_MOESM3_ESM.gif
Alonso PL, Brown G, Arevalo-Herrera M, Binka F, Chitnis C, Collins F, Doumbo O, Greenwood B, Hall BF, Levine MM, Mendis K, Newman RD, Plowe CV, Rodríguez MH, Sinden R, Slutsker L, Tanner M: A research agenda to underpin malaria eradication: drugs. PLoS Med. 2011, 8: e1000402- CrossRef
World Health Organization: World Malaria Report. 2010, World Health Organization, Geneva
World Health Organization: Guidelines for the treatment of malaria, Second Edition. 2010, Geneva, Switzerland
Dondorp AM, Nosten F, Yi P, Das D, Phyo AP, Tarning J, Lwin KM, Ariey F, Hanpithakpong W, Lee SJ, Ringwald P, Silamut K, Imwong M, Chotivanich K, Lim P, Herdman T, An S, Yeung S, Singhasivanon P, Day NPJ, Lindegardh N, Socheat D, White NJ: Artemisinin resistance in Plasmodium falciparum malaria. N Engl J Med. 2009, 361: 455-67. 10.1056/NEJMoa0808859. PubMedCentralCrossRefPubMed
World Health Organization: Methods and techniques for assessing exposure to antimalarial drugs in clinical field studies. 2011, Geneva, Switzerland
Mentre F, Mallet A, Baccar D: Optimal design in random-effects regression models. Biometrika. 1997, 84: 429-442. 10.1093/biomet/84.2.429. CrossRef
Duffull SB: POPT - Installation and user guide. Ver 3.0. 2006, [ http://www.winpopt.com]
Simpson JA, Price R, ter Kuile F, Teja-Isavatharm P, Nosten F, Chongsuphajaisiddhi T, Looareesuwan S, Aarons L, White NJ: Population pharmacokinetics of mefloquine in patients with acute falciparum malaria. Clin Pharm Ther. 1999, 66: 472-484. 10.1016/S0009-9236(99)70010-X. CrossRef
Bangchang KN, Davis T, Looareesuwan S, White N, Bunnag D, Karbwang J: Mefloquine pharmacokinetics in pregnant women with acute falciparum malaria. Trans R Soc Trop Med Hyg. 1994, 88: 321-323. 10.1016/0035-9203(94)90101-5. CrossRef
Svensson US, Alin MH, Karlsson MO, Bergqvist Y, Ashton M: Population pharmacokinetic and pharmacodynamic modelling of artemisinin and mefloquine enantiomers in patients with falciparum malaria. Eur J Clin Pharm. 2002, 58: 339-351. 10.1007/s00228-002-0485-y. CrossRef
Tarning J, McGready R, Lindegardh N, Ashley EA, Pimanpanarak M, Kamanikom B, Annerberg A, Day NPJ, Stepniewska K, Singhasivanon P, White NJ, Nosten F: Population pharmacokinetics of lumefantrine in pregnant women treated with artemether-lumefantrine for uncomplicated Plasmodium falciparum malaria. Antimicrob Agents Chemother. 2009, 53: 3837-3846. 10.1128/AAC.00195-09. PubMedCentralCrossRefPubMed
Hietala S, Martensson A, Ngasala B, Dahlström S, Lindegardh N, Annerberg A, Premji Z, Farnert A, Gil P, Bjorkman A, Ashton M: Population pharmacokinetics and pharmacodynamics of artemether and lumefantrine during combination treatment in children with uncomplicated falciparum malaria in Tanzania. Antimicrob Agents Chemother. 2010, 54: 4780-4788. 10.1128/AAC.00252-10. PubMedCentralCrossRefPubMed
Tarning J, Ashley EA, Lindegardh N, Stepniewska K, Phaiphun L, Day NPJ, McGready R, Ashton M, Nosten F, White NJ: Population pharmacokinetics of piperaquine after two different treatment regimens with dihydroartemisinin-piperaquine in patients with Plasmodium falciparum malaria in Thailand. Antimicrob Agents Chemother. 2008, 52: 1052-1061. 10.1128/AAC.00955-07. PubMedCentralCrossRefPubMed
Hietala S, Bhattarai A, Röshammar MMD, Ali AS, Strömberg J, Hombhanje FW, Kaneko A, Björkman A, Ashton M: Population pharmacokinetics of amodiaquine and desethylamodiaquine in pediatric patients with uncomplicated falciparum malaria. J Pharmacokinet Pharmacodyn. 2007, 34: 669-686. 10.1007/s10928-007-9064-2. CrossRefPubMed
Jullien V, Ogutu B, Juma E, Carn G, Obonyo C, Kiechel J: Population pharmacokinetics and pharmacodynamic considerations of amodiaquine and desethylamodiaquine in Kenyan adults with uncomplicated malaria receiving artesunate-amodiaquine combination therapy. Antimicrob Agents Chemother. 2010, 54: 2611-2617. 10.1128/AAC.01496-09. PubMedCentralCrossRefPubMed
Ashley EA, Stepniewska K, Lindegardh N, McGready R, Hutagalung R, Hae R, Singhasivanon P, White NJ, Nosten F: Population pharmacokinetic and pharmacodynamic modelling of artemisinin and mefloquine enantiomers in patients with falciparum malaria. Antimicrob Agents Chemother. 2006, 50: 2281-2285. 10.1128/AAC.00040-06. PubMedCentralCrossRefPubMed
Beal SL, Sheiner LB, Boeckmann AJ: NONMEM Users Guides. 1989-2006, Icon Development Solutions, Ellicott City
Tarning J, Zongo I, Somé FA, Rouamba N, Parikh S, Rosenthal PJ, Hanpithakpong W, Jongrak N, Day NPJ, White NJ, Nosten F, Ouedraogo JB, Lindegardh N: Population pharmacokinetics and pharmacodynamics of piperaquine in children with uncomplicated falciparum malaria. Clin Pharmacol Ther. 2012, 91: 497-505. 10.1038/clpt.2011.254. PubMedCentralCrossRefPubMed
Tarning J, Rijken MJ, McGready R, Phyo AP, Hanpithakpong W, Day NPJ, White NJ, Nosten F, Lindegardh N: Population pharmacokinetics of dihydroartemisinin and piperaquine in pregnant and non-pregnant women with uncomplicated malaria. Antimicrob Agents Chemother. 2012, Jan 17: epub ahead of print
Rijken M, McGready R, Jullien V, Tarning J, Lindegardh N, Phyo AP, Win AK, Hsi P, Cammas M, Singhasivanon P, White N, Nosten F: Pharmacokinetics of amodiaquine and desethylamodiaquine in pregnant and postpartum women with Plasmodium vivax malaria. Antimicrob Agents Chemother. 2011, 55: 4338-4342. 10.1128/AAC.00154-11. PubMedCentralCrossRefPubMed
- Optimal designs for population pharmacokinetic studies of the partner drugs co-administered with artemisinin derivatives in patients with uncomplicated falciparum malaria
Kris M Jamsen
Stephen B Duffull
Nicholas J White
Julie A Simpson
- BioMed Central
Neu im Fachgebiet Innere Medizin
Meistgelesene Bücher aus der Inneren Medizin
Mail Icon II